✦ LIBER ✦

Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function

✍ Scribed by R. H. Barbhaiya; M. E. Brady; U. A. Shukla; D. S. Greene

Publisher: Springer
Year: 1995
Tongue: English
Weight: 604 KB
Volume: 49
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00192384

No coin nor oath required. For personal study only.

✦ Synopsis

The steady-state pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were compared in subjects with normal and impaired renal function. Patients: The Study was of parallel group design which included 7 subjects with normal (NOR) renal function, CLcR > 72 ml'min -1' 1.73 m -2, 6 with moderate (MOD) renal impairment, CLcR 31-60 ml'min 1.1.73 m -2 and 9 with severe (SEV) renal impairment, CLcR < 30 ml. min -1' 1.73 m 2. Subjects in each renal function group received a 100-mg oral dose of nefazodone hydrochloride BID for 7 days and a single morning dose on day 8. Starting 48 h after the last 100-mg dose, 200-mg doses were administered on a similar schedule to 3, 4 and 3 subjects from each renal function group (NOR, MOD and SEV, respectively). Single trough blood samples just prior to each

📜 SIMILAR VOLUMES

Pharmacokinetics of naproxen in subjects

Pharmacokinetics of naproxen in subjects with normal and impaired renal function

✍ M. Anttila; M. Haataja; A. Kasanen 📂 Article 📅 1980 🏛 Springer 🌐 English ⚖ 473 KB

Pharmacokinetics of nicorandil in patien

Pharmacokinetics of nicorandil in patients with normal and impaired renal function

✍ M. Molinaro; G. Villa; M. B. Regazzi; A. Salvadeo; S. Segagni; R. Rondanelli; E. 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 489 KB

The pharmacokinetics of oral nicorandil 20 mg 12 hourly for 9 doses was evaluated in 21 hospitalized patients with angina pectoris due to coronary heart disease and with normal and impaired renal function. Patients were divided into 3 groups based on creatinine clearance (CLCr): GROUP I (n = 6) grea

Pharmacokinetics of cephacetrile in pati

Pharmacokinetics of cephacetrile in patients with normal or impaired renal function

✍ A. Domínguez-Gil; M. C. Castiñeiras; J. M. Tabernero; J. L. Rodríguez Colmmes; S 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 425 KB

Pharmacokinetics of cefoxitin in patient

Pharmacokinetics of cefoxitin in patients with normal or impaired renal function

✍ M. J. Garcia; A. Dominguez-Gil; J. M. Tabernero; J. A. Sanchez Tomero 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 596 KB

Single-dose pharmacokinetics of nefazodo

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

✍ R. H. Barbhaiya; D. S. Greene; U. A. Shukla 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 658 KB

The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < 55 years of age (YNG), 12 elderly subjects > 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis

Pharmacokinetics of lisinopril in hypert

Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function

✍ B. A. M. van Schaik; G. G. Geyskes; P. A. van der Wouw; H. H. van Rooij; A. J. P 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 551 KB